March’s $13 billion in U.S. venture funding looks, at first glance, like a sharp contraction. In reality, it represents a return to ordinary late-stage activity after February’s statistical outlier—a month distorted by the unprecedented $110 billion OpenAI transaction and a cluster of other oversized AI finance events. When the baseline is a once‑in‑a‑decade anomaly, the subsequent normalization can appear like a downturn even when underlying conditions remain stable.
The distortion becomes clearer when the February components are isolated. The OpenAI deal alone reshaped the month’s totals. Add Anthropic’s $30 billion financing and Waymo’s $16 billion raise, and February becomes an aggregation of events unlikely to repeat in either scale or timing. These were exceptional transactions, not indicators of structural acceleration. Using them as a benchmark sets an unrealistic comparison point for March.
By contrast, early‑stage activity has shown little deviation across the first quarter. Seed and Series A volumes in January, February, and March track within typical quarterly variance, signaling that investor appetite for foundational innovation remains steady. The apparent slowdown is concentrated almost entirely in late‑stage checks, and even there the change reflects the absence of megadeals rather than a collapse in demand or capital availability.
Geopolitical tension—including market unease around the Iran conflict—coincided with March’s numbers, but it does not fully account for the gap. Volatility affected public markets more directly than private deployments, and there is limited evidence that U.S. VCs paused allocations in response. The magnitude of the February distortion simply overwhelms any incremental macro signal.
A useful counterpoint comes from Europe, where March delivered the region’s strongest month of the year. Large raises such as Nscale’s and AMI’s point to robust capital accessibility and a functioning late‑stage pipeline. If global liquidity were tightening in a meaningful way, Europe would not be posting its peak month while the U.S. shows a trough.
For investors calibrating deployment pace, the takeaway is straightforward: March should be benchmarked against typical late‑stage comps, not against an anomalous AI surge that inflated February beyond any realistic baseline. Viewed through that lens, the market looks stable, disciplined, and directionally healthier than headline figures suggest.
